⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 8, 2025

Figure S7 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Zahra Davoudi Thomas S. Dexheimer Nathan P. Coussens Thomas Silvers Raymond G. Fox Samantha B. Kemp Poorva Juneja Joel Morris Melinda G. Hollingshead Naoko Takebe James H. Doroshow Beverly A. Teicher

View Full Paper

Ask AI

Bookmark

Share

Key Points

Combination of BI-3406 and trametinib shows significant activity in multicell-type tumor spheroids, indicating synergistic effects against KRAS variants.
Notable combination activity observed in patient-derived spheroids from various cancer types with KRAS mutations, enhancing treatment efficacy.
Assessment utilized a structured analysis of tumor spheroids to evaluate interplay between targeted agents and Ras pathway inhibitors.
Findings may inform future therapeutic strategies, highlighting the need for further exploration in clinical settings.

Implication

Analysis shows combination of BI-3406 and trametinib enhances activity in multicell-type tumors, suggesting potential for various cancer types.

Abstract

Figure S7. Combination activity of BI-3406 with trametinib in multicell-type tumor spheroids.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davoudi et al. (2025) studied this question.

synapsesocial.com/papers/68e861857ef2f04ca37e3bd0 https://doi.org/10.1158/2767-9764.30304681

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S10 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
2Figure S8 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
3Figure S13 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
4Figure S4 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
5Figure S14 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025